BEIJING, Oct. 30, 2025 /PRNewswire/ — To thoroughly study, promote, and implement Xi Jinping Thought on Culture and to advance mutual learning between Chinese and foreign civilizations, the Global Times “Reading Through the Seasons” China-South Korea Literature Salon was held on Wednesday at the Korean Cultural Center, China. The event aimed to build a new platform for cultural exchange between China and South Korea through literary dialogue.

Jointly presented by the Global Times, the Korean Cultural Center, and the World Sinology Center at Beijing Language and Culture University (BLCU), the event brought together renowned writers and translators from both countries to explore the charm of literature and listen to the symphony of East Asian literature through bilingual verses infused with the fragrance of ink. It was also a continuation of the Global Times’ “Reading Through the Seasons” series of events.

Bai Long, deputy editor-in-chief of the Global Times, said in his opening speech that he hopes this event will deepen cultural exchanges between the two countries, foster closer dialogue and more frequent mutual translations among writers, scholars, and publishers, and inspire the younger generation to explore through reading and creation the common challenges faced by humanity. 

Bai noted that the Global Times has long been a witness, recorder, and promoter of literary dialogue and cultural exchange between China and South Korea.

Kim Jin-gon, director of the Korean Cultural Center, China, told the Global Times that South Korea and China are close in geography, connected in culture, and bound by deep people-to-people ties – precious neighbors inseparably linked to each other.

Xu Baofeng, director of the World Sinology Center at BLCU, said young people represent the future of both China and South Korea, and the future of Asia. “We hope that through events like today’s literary salon, dialogue between Chinese and South Korean literature will spark new inspiration and meaningful exchanges of ideas.”

During the salon, Kim Tae-sung, a South Korean translator and winner of the 10th Special Book Awards of China; Dong Xi, president of the Guangxi Writers Association and professor at Guangxi Minzu University; South Korean writer Lee Jee; and Cui Youxue, associate professor at the School of Chinese Ethnic Minority Languages and Literature, Minzu University of China, shared their journey on the literary exchanges between China and South Korea. 

At the following roundtable discussion, Yin Hanchao, deputy director of the Chinese Studies Center of the National Library of China, said that China and South Korea both belong to the Confucian cultural sphere, therefore share common values and ways of thinking in this regard.

The speakers at the roundtable elaborated on topics such as the locality and globality of contemporary literature from both countries in the context of globalization.

In a major move of advocating for reading and literary exchanges, student representatives from China and South Korea and the hosts jointly launched a reading initiative, calling on youths from the two countries to use books as a bridge and transform literary wisdom into a driving force for action.

Since 2023, the Global Times has hosted five offline events featuring reading and literature.

Bai Long, deputy editor-in-chief of the Global Times: 

From the records of ancient Korean envoys documenting the customs and landscapes of China to the wide circulation of contemporary Chinese and South Korean literary works, books have always served as vital vessels of civilization, bonds of emotion between the two peoples, and witnesses to shared history and changing times. The vibrancy of economic and trade exchanges, coupled with the resonance between civilizations, together paints a colorful picture of the bilateral relationship and provides fertile ground for literary exchanges between China and South Korea.

Kim Jin-gon, director of the Korean Cultural Center, China:

Personally, I believe that literature is the essence of culture. When it is translated into other languages, it becomes the most accessible and profound medium for mutual understanding. I hope that today’s literary salon will serve as an opportunity to further expand exchanges and cooperation between South Korea and China in the fields of translation and publishing, deepening mutual understanding and friendship between our peoples.

Xu Baofeng, director of the World Sinology Center at BLCU:

China and South Korea share deep bonds between their peoples and a natural affinity in culture and literature, giving them unique advantages in fostering people-to-people exchanges. The World Sinology Center at BLCU will continue to work with all partners, using language as a medium and culture as a bridge, to deepen academic cooperation. Together, we hope to help Chinese and South Korean literature resonate in harmony through mutual learning, and to steer the vessel of literary friendship between our two countries across mountains and seas toward a brighter shore.

Kim Tae-sung, South Korean translator, winner of the 10th Special Book Awards of China:

South Korea is one of the countries that has absorbed the most Chinese cultural content… If you go right now to a large bookstore in Seoul, how many books related to China can you find? At least more than 1,000. Books related to Lu Xun alone exceed 100. This is probably because, as the nearest neighboring country, there is an urgent need to understand and gain knowledge about China.

Dong Xi, president of the Guangxi Writers Association, professor at Guangxi Minzu University:

Chinese and South Korean literature use the narrative shell of “transformation” to convey distinct themes. Writers from different eras and countries have all employed the motif of “transformation” to express their unique experiences and themes. Every form of “transformation” exists to achieve a sense of normalcy.

Lee Jee, South Korean writer:

Just as flowers, though sharing the same roots, blooming in different colors due to variations in soil and climate, South Korean and Chinese literature have become richer through their differences. If the globalization of literature has been advanced through translation, then the current intergenerational shift is creating another turning point. Readership has undergone more rapid and radical changes in the past decade than those witnessed over the previous hundred years.

Cui Youxue, associate professor at School of Chinese Ethnic Minority Languages and Literature, Minzu University of China:

I would like to share with you my understanding of the poetic nature of Han Kang’s literature… The poetic quality of Han’s works stems from her steadfast commitment to writing poetry and her continuous effort to infuse poetic elements into fiction.

Yin Hanchao, deputy director of the Chinese Studies Center of the National Library of China:

China and South Korea both belong to the Confucian cultural sphere, therefore share common values and ways of thinking in this regard. Chinese works To Live, Chronicle of a Blood Merchant and South Korea’s Stingray all portray fathers as responsible and devoted figures. Such universal cultural symbols resonate deeply across regions and help people empathize with one another.

Roundtable discussions

Chinese and South Korean guests communicated on reading and literary exchanges between the two countries during a roundtable session at the event.

Reading begins with our neighbors, said Dong Xi. Many of our literature courses today take a long detour before paying attention to East Asian authors. Yet when we read South Korean works, there’s a sense of familiarity: We share the same roots, our cultures are similar, and the issues we face are often alike. The most important aspect of universality lies in humanity: If a work embodies genuine human emotions, it will move readers all over the world.

Yin Hanchao said that, from a translator’s perspective, Chinese translators were already thinking about how to better translate Chinese works for the world more than a century ago. For a nation to have the vision and confidence to present its own works to the world for others to appreciate, judge, or even critique, that in itself is a true expression of cultural confidence.

In Kim Tae-sung’s view, language is the vessel of culture, and the only means to digest it is through reading. He said Chinese author Liu Zhenyun’s novels possess a kind of narrative humor, while Dong Xi’s works are remarkable for their skillful use of metaphor. Both are distinctive qualities of Chinese writers. South Korean literature should engage in deeper exchanges with Chinese literature, he said.

As a novelist, Lee Jee said we should foster closer literary exchanges through fiction. Only works written with tears and blood can evoke true empathy among people around the world – that’s how they travel beyond borders.

According to Cui Youxue, for translators, all literary history is essentially a history of translation. He believes translators have made great contributions to the development of national literatures, languages, and even to the formation of nations themselves. Reading, in turn, is a form of spiritual communication: A good novel can profoundly move the heart, and those who read feel spiritually fulfilled every day.

BEIJING, Oct. 30, 2025 /PRNewswire/ — Jenscare Scientific Co., Ltd. (“Jenscare” or the “Company”) (HKEX: 9877), an innovative medical device company, recently released 6-month follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes and challenging cases of JensClip and Ken-Valve, a proprietary TMVr system and TAVR (AR) system respectively, representing the Company’s diversified and high-potential multi-product portfolio, at TCT 2025 in the U.S..

6-Month Follow-up Results of LuX-Valve Plus TRINITY Study
-Released by Prof. Thomas Modine, CHU de Bordeaux-Haut-Leveque, France

TRINITY is a global prospective, multicenter, single-arm clinical trial, which primarily aims to evaluate the safety and efficacy of LuX-Valve Plus in application on patients with severe tricuspid regurgitation and high surgical risk. The study enrolled 161 patients from 20 centers around the world, among which, 18 centers were from France, Germany, Spain, Denmark, and the UK.

The average age of the patients (FAS + Roll-in group) is about 77 years old with an average STS score of 10.24%. 91.93% of the patients has atrial fibrillation, 32.92% has left heart surgery/intervention, 26.71% has pacemaker/ICD implanted. Patients are combined with multi other comorbidities, which formed a poor baseline and increased the risks of surgical treatment or difficulties of other interventional therapies. Over 75% of enrollments utilized valve sizes between 55mm and 70mm. The results show that the device success rate is about 97%, and the average device operation time is around 41.60 minutes with the shortest time being 11 minutes.

The safety indicators show that the overall CEC-adjudicated composite events rate at 6-month of FAS + Roll-in group is 19.9%. Cardiovascular mortality is 3.7%, the incidence of strokes is 0.6%, new onset renal failure is 1.2%, non-selective tricuspid valve surgery/intervention post procedure is 2.5%, major cardiac structural complications is 3.1%, severe bleeding (including fatal, life-threatening and extensive bleeding as defined by MVARC) is 5.0%, new pacemaker implantation due to AVB is only 8.7% (no change compared to that at 30 days). No events prevailed in myocardial infarction, major access site and vascular complications, and device-related pulmonary embolism.

The efficacy indicators show that the tricuspid regurgitation (TR) grade, NYHA classification, and QoL improved significantly at 6 months. 94.4% of the patients show no above moderate TR. 90.9% of them show postoperative NYHA class I/II. KCCQ score increased by around 19 pts on average. 6MWD increased by 39 meters on average.

Professor Thomas Modine concluded that LuX-Valve Plus TTVR system is an innovative device indicated for high-surgical risk patients with severe TR and demonstrates several advantages. First, it has radial-force independent anchoring mechanism, which is designed particularly for TV. Second, it indicates low demands on imaging quality, which is expected to significantly reduce device time. Third, it provides large size options, which enables wide applicability on large TV anatomies. The 6-month clinical outcomes of TRINITY Trial demonstrate good safety and performances, with improvements in quality of life and low rate of composite adverse events. The wide application on large anatomy patients provides encouraging treatment options for severe TR patients, while current therapies are limited. Further follow-ups of TRINITY trial and clinical evidence worldwide using LuX-Valve Plus system are underway. Currently, the U.S. FDA IDE-EFS for LuX-Valve Plus has completed full enrollment with excellent safety and efficacy outcomes.

Meanwhile, evidence supporting the efficacy and safety of the transjugular approach for LuX-Valve Plus was also presented. The advantages of the transjugular approach include low incidence of access site bleeding complications, reflecting high safety profile; shorter device operation time, demonstrating good procedural efficiency; and a low screening failure rate due to the anatomical structure of the jugular vein. Current data from the TRAVEL II and TRINITY studies show bleeding complication rates of 0% and 1.8% respectively, representing outstanding clinical outcomes.

One-Year Follow-Up Results of JensClip
-Released by Prof. Vinicius Esteves, University Hospitals in Cleveland, U.S.

The study of JensClip TMVr system is a prospective, multicenter, single-arm clinical trial, which primarily aims to evaluate the safety and efficacy of JensClip in application on patients with symptomatic degenerative mitral regurgitation (DMR) at high surgical risk. The study enrolled 114 patients from 18 centers in China.

The average age of the patients is about 71 years old with an average STS score of 7.65%. 63.2% of the patients has hypertension history, 41.2% has coronary artery disease, 30.7% has atrial fibrillation, and 91.2% has pre-operative NYHA class III/IV. The results show that the device success rate at 30 days is about 95%, and the average device operation time is around 67.53 minutes.

The safety indicators show that the all-cause mortality rate is 1.8%. The incidence of unplanned mitral valve intervention/surgery is 5.3%, and that of stroke is 1.8%. The incidence of renal failure, myocardium infarction, major bleeding, device releasing/locking failure, and clip related hemolysis are all 0.9%. No events prevailed in SLDA and device related air embolism.

The efficacy indicators show that the mitral regurgitation (MR) grade, NYHA classification, and QoL improved continuously at 1 year. 96.29% of the patients show no above moderate MR. 93.46% of them show postoperative NYHA class I/II. KCCQ score increased by around 20 pts on average. 6MWD increased by around 82m from the baseline.

Professor Vinicius Esteves concluded that JensClip is an innovative device intended for severe DMR, providing easy and reliable operation with unique designing features like continuous-adjustable locking system and independent grasping technique. The 1-year clinical outcomes demonstrated procedural safety and durable MR reduction.

One-Year Follow-Up Results of Ken-Valve
-Released by Prof. Anson Cheung, St. Paul’s Hospital, Canada

The study of Ken-Valve TAVR system is a prospective, multicenter, single-arm clinical trial, which primarily evaluates the safety and efficacy of Ken-Valve in application on patients with symptomatic aortic regurgitation (or combined with aortic stenosis) at high surgical risk. The study enrolled 142 patients from 15 centers in China.

The average age of the patients is about 70 years old with an average STS score of 5.87%. 61.97% of the patients has moderate to severe frailty, 71.83% has hypertension history, 42.96% has coronary artery disease, 48.59% has peripheral vascular disease, 51.41% has prior surgical history, and 99.30% has pre-operative NYHA class III/IV. The results show that the device success rate is about 97%, and the average device operation time is around 8.70 minutes.

The safety indicators show that all-cause mortality is 5.63%. The incidence of severe bleeding is 4.23%, and conversion to surgery is 1.41%. Both the incidence rate of stroke and valve migration is 2.11%. Both the incidence of acute renal dysfunction and needed for cardiopulmonary mechanical assistance is 0.7%. No events prevailed in coronary artery obstruction, thrombosis, and cardiac tamponade.

The efficacy indicators show that the aortic regurgitation (AR) reduction, NYHA classification, and QoL improved continuously at 1 year. 94.7% of the patients show no above moderate paravalvular leakage. 96.2% of them show postoperative NYHA class I/II. EQ-5D score increased by around 19 pts on average. The function and performance of Ken-Valve remain favorable with stable EOA and transvalvular gradient at 1 year.

Professor Anson Cheung concluded that Ken-Valve TAVR system is an innovative device indicated for high-surgical risk patients with severe AR or predominantly regurgitant mixed with aortic valve stenosis with several advantages. Ken-Valve has integrated clamping and radial force anchoring mechanism which can provide reliable anchoring force. It has a leak-proof ring which is expected to minimize PVL post-implantation. It provides large size options which enables wide applicability on large aortic valve anatomies. The deflectable delivery system allows better co-axiality and alignment when treating complex anatomies like horizontal heart. The 1-year clinical outcomes of the Ken-Valve Pivotal Trial demonstrated good safety and performances, with improvements in quality of life, stable EOA and transvalvular gradient, and low rate of composite adverse events. The wide application on large anatomy patients provides encouraging treatment options for severe AR patients while current therapies are limited.

About LuX-Valve Plus

LuX-Valve Plus, the proprietary TTVR system, is designed for patients with severe tricuspid TR and high surgical risk. LuX-Valve Plus breaks through multiple technical difficulties in tricuspid valve interventional therapy. With the design of innovative “interventricular septum anchoring” and “leakproof self-adaptive braided ring”, which enables non-radial anchoring of the valve implant and tend to effectively prevent AV block. LuX-Valve series product is designated by the FDA as a breakthrough device, is enrolled in the Total Product Life Cycle Advisory Program (TAP) pilot of the FDA and is selected for the Expert Panel Scientific Advice Pilot by the EMA. As of the latest update, close to 1000 implantation cases have been completed worldwide with the LuX-Valve series products, and the longest follow-up record has been over 6 years.

About JensClip

JensClip, the proprietary TMVr system, features an innovative self-locking design, which is expected to effectively improve mitral regurgitation and reduce leaflet tension. The valve clip allows for flexible shape adjustments, which is expected to enhance procedural safety and improve intraoperative maneuverability. Furthermore, its one-piece release mechanism is designed to minimize potential mis-operation risks associated with staged detachment, effectively reducing device operation time.

About Ken-Valve

Ken-Valve, the proprietary first-generation TAVR system, is designed for the treatment of patients with severe AR or combined with AS. Its innovative design accommodates a wide range of complex anatomies, significantly improving procedural safety and flexibility while reducing device operation time. It offers six annulus sizes – 23mm, 25mm, 27mm, 29mm, 31mm and 33mm. Its unique innovative design and applicability to complex anatomical challenges, such as large annulus and horizontal heart, can address the treatment needs of patients with large annulus for whom treatment options are relatively limited.

About Jenscare

Jenscare is an innovative medical device company, established in 2011. The Company has achieved a diversified and high-potential product portfolio of interventional treatment solutions for different types of structural heart diseases, including tricuspid valve disease, mitral valve disease, aortic valve disease and so on. The Company is continuing to expand its global business layout, enhancing product influence and clinical application scale, thereby laying a solid foundation for sustained high-speed growth.